You are here
From patented antibodies to tumour-associated cell surface markers, we have a diverse portfolio of agents from pre-clinical to phase 1 clinical development available for collaborative development and/or licensing.
In collaboration with Universities of Oxford and Leicester our CRUK-AstraZeneca Antibody Alliance Laboratory has developed a first-in-class, inhibitory antibody specific for human ARG2.Read more
Licensing/collaborative opportunity around unique FcɣR-independent “super-agonistic” 4-IBB mABs containing a propriety hinge technology that promotes both CD8+ T cell activation and the depletion oRead more
We are seeking a partner experienced in the field of cell therapy development and in the Chinese regulatory environment to take this technology through to first in man trials in China.Read more
CRUK is seeking an industry partner for co-development and/or exclusive licensing of its CLEC14A IP, materials and know-how, to progress anti-CLEC14A antibodies into first-in-human clinical studiesRead more